These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 16797237)

  • 1. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.
    Watanabe T; Masuyama J; Sohma Y; Inazawa H; Horie K; Kojima K; Uemura Y; Aoki Y; Kaga S; Minota S; Tanaka T; Yamaguchi Y; Kobayashi T; Serizawa I
    Clin Immunol; 2006 Sep; 120(3):247-59. PubMed ID: 16797237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
    Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
    Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD52 ligation induces CD4 and CD8 down modulation in vivo and in vitro.
    Shah A; Lowenstein H; Chant A; Khan A
    Transpl Int; 2006 Sep; 19(9):749-58. PubMed ID: 16918536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes.
    Rowan WC; Hale G; Tite JP; Brett SJ
    Int Immunol; 1995 Jan; 7(1):69-77. PubMed ID: 7718516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex-vivo expanded baboon CD4+ CD25 Hi Treg cells suppress baboon anti-pig T and B cell immune response.
    Singh AK; Seavey CN; Horvath KA; Mohiuddin MM
    Xenotransplantation; 2012; 19(2):102-11. PubMed ID: 22497512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased CD4+CD25+Foxp3+ regulatory T cells in tolerance induced by portal venous injection.
    He F; Chen Z; Xu S; Cai M; Wu M; Li H; Chen X
    Surgery; 2009 Jun; 145(6):663-74. PubMed ID: 19486771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B7+ iris pigment epithelial cells convert T cells into CTLA-4+, B7-expressing CD8+ regulatory T cells.
    Sugita S; Keino H; Futagami Y; Takase H; Mochizuki M; Stein-Streilein J; Streilein JW
    Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5376-84. PubMed ID: 17122127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agonistic anti-4-1BB antibody promotes the expansion of natural regulatory T cells while maintaining Foxp3 expression.
    Zhang P; Gao F; Wang Q; Wang X; Zhu F; Ma C; Sun W; Zhang L
    Scand J Immunol; 2007 Oct; 66(4):435-40. PubMed ID: 17850588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
    Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
    Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.
    Blazar BR; Sharpe AH; Taylor PA; Panoskaltsis-Mortari A; Gray GS; Korngold R; Vallera DA
    J Immunol; 1996 Oct; 157(8):3250-9. PubMed ID: 8871619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease.
    Koenecke C; Lee CW; Thamm K; Föhse L; Schafferus M; Mittrücker HW; Floess S; Huehn J; Ganser A; Förster R; Prinz I
    J Immunol; 2012 Sep; 189(6):2890-6. PubMed ID: 22869903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia.
    Rezvany MR; Tehrani MJ; Karlsson C; Lundin J; Rabbani H; Osterborg A; Mellstedt H
    Br J Haematol; 2006 Nov; 135(4):475-85. PubMed ID: 16995884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses.
    Kitazawa Y; Fujino M; Wang Q; Kimura H; Azuma M; Kubo M; Abe R; Li XK
    Transplantation; 2007 Mar; 83(6):774-82. PubMed ID: 17414712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-2-independent generation of FOXP3(+)CD4(+)CD8(+)CD25(+) cytotoxic regulatory T cell lines from human umbilical cord blood.
    Nakamura S; Suzuki M; Sugimoto A; Tsuji-Takayama K; Yamamoto M; Otani T; Inoue T; Harashima A; Okochi A; Motoda R; Yamasaki F; Orita K; Kibata M
    Exp Hematol; 2007 Feb; 35(2):287-96. PubMed ID: 17258077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-2 contributes to maintaining a balance between CD4+Foxp3+ regulatory T cells and effector CD4+ T cells required for immune control of blood-stage malaria infection.
    Berretta F; St-Pierre J; Piccirillo CA; Stevenson MM
    J Immunol; 2011 Apr; 186(8):4862-71. PubMed ID: 21389253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of bystander T helper 1 cells by iris pigment epithelium-inducing regulatory T cells via negative costimulatory signals.
    Sugita S; Horie S; Yamada Y; Keino H; Usui Y; Takeuchi M; Mochizuki M
    Invest Ophthalmol Vis Sci; 2010 May; 51(5):2529-36. PubMed ID: 19959639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A kinetic comparative study on lymphocyte responses to superantigen and phytohemagglutinin: reciprocal presentation of superantigen on the surface of activated lymphocytes.
    Ijichi S; Yamano Y; Osame M; Hall WW
    Cell Immunol; 1996 Nov; 173(2):312-6. PubMed ID: 8912892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes.
    Brillard E; Pallandre JR; Chalmers D; Ryffel B; Radlovic A; Seilles E; Rohrlich PS; Pivot X; Tiberghien P; Saas P; Borg C
    Exp Hematol; 2007 Mar; 35(3):416-25. PubMed ID: 17309822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis.
    Jordan MB; McClain KL; Yan X; Hicks J; Jaffe R
    Pediatr Blood Cancer; 2005 Mar; 44(3):251-4. PubMed ID: 15390358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo expanded human CD4+CD25+Foxp3+ regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD).
    Cao T; Soto A; Zhou W; Wang W; Eck S; Walker M; Harriman G; Li L
    Cell Immunol; 2009; 258(1):65-71. PubMed ID: 19410243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.